Business Context and Reporting Period
This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of September 2017, with a specific reporting date of September 27, 2017. The registrant is a foreign private issuer incorporated in Belgium, headquartered in Mechelen. The filing serves to incorporate by reference a press release (Exhibit 99.1) issued on the same date.
Financial Metrics
The filing text does not provide specific financial data. No values are disclosed for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing acts solely as a conduit for the attached press release.
Material Changes
The document does not contain comparative financial data or explicit statements regarding material changes versus prior periods. The primary content is the incorporation of a press release, the specific details of which are not included in the provided text.
Guidance, Outlook, and Risks
Management commentary, guidance, and risk factors are not detailed in the filing text itself. The document notes that the press release contains quotes from Prof. Diamant Thaci, Dr. Piet Wigerinck, and Dr. Malte Peters, but the substance of these quotes is not provided. The filing incorporates the press release into various Registration Statements (Forms F-3 and S-8).
Key Facts for Investor Verification
- Verify the actual content of the Exhibit 99.1 press release dated September 27, 2017, as the filing text only references it without summarizing its substance.
- Confirm the registrant is Galapagos NV, noting a discrepancy with the metadata company name "Lakefront Biotherapeutics NV."
- Check the referenced Registration Statements (File Nos. 333-211765, 333-204567, 333-208697, 333-211834, 333-215783, and 333-218160) for the full context of the incorporated information.
- Review the press release for the specific details regarding the quotes from Prof. Diamant Thaci, Dr. Piet Wigerinck, and Dr. Malte Peters.